Title : Frameless stereotactic radiotherapy alone and combined with temozolomide for canine gliomas
Abstract:
We evaluated stereotactic volume modulated arc radiotherapy (VMAT RT) for canine gliomas, alone (RT) and in combination with temozolomide (RT+TMZ), compared to palliation. Overall and disease-specific survival times were estimated. Thirty dogs were palliated, 22 dogs were treated with RT and 20 with RT+TMZ. Complete and partial responses were observed in 63.2% and 90.9% of patients in the RT and RT+TMZ arms, respectively, that were alive at one year. Median survival in the palliation arm was 94 days. Median survivals of the RT arm (383 days) and RT+TMZ arm (420 days) were not significantly different (p=0.61). Positive correlation with survival was found both for the ratio between target and brain (relative) volume of the tumor of <5% (p=0.013) and for a clinical presentation with normal mentation (p=0.032). Volume modulated arc radiotherapy is feasible and effective for canine brain gliomas. Combining this therapy with TMZ did not elicit any additional improvement in survival time.
